TrialJournal of clinical pharmacology2026

Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment.

Janneke M Brussee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.